While investors have been fixated on the fate of the blockbuster Resulticks acquisition, Diginex quietly brought an entirely new supply chain management platform to market. The end‑to‑end solution, dubbed Risk‑to‑Remedy, went live in early June, combining existing tools LUMEN and APPRISE with fresh grievance mechanisms. The launch targets a niche that is anything but small — experts peg the global market for human rights and supply chain due diligence at roughly $3.8 billion for 2025.
The timing is notable, given that regulatory tailwinds are shifting rather than disappearing. The EU’s Corporate Sustainability Due Diligence Directive (CSDDD) has faced delays, pushing national implementation to July 2028 and full application to mid‑2029. The scope has narrowed to companies with more than 5,000 employees and €1.5 billion in revenue, softening near‑term compliance pressure on potential clients. Yet the structural demand for software that monitors supply chain risk remains intact, giving Diginex a longer runway to consolidate its position in this space.
The silence that speaks volumes
For all the promise of Risk‑to‑Remedy, the market’s attention remains stubbornly glued to the Resulticks transaction. The extended deadline for the takeover — set for June 12 — has now passed, and management has issued no update. That radio silence has weighed heavily on the stock.
On Friday, Diginex shares slipped another 7% to close at $0.90, compounding a monthly slide of 25%. The weekly decline stood at 10%. The relative strength index has plunged to 28.2, a reading that signals deeply oversold territory. Annualized volatility of 124% underscores the jittery mood among holders.
At the heart of the deal hangs a huge transformation. Resulticks would contribute an estimated $150 million in annual revenue and EBITDA of between $46 million and $50 million — figures that dwarf Diginex’s current market capitalization of $34 million and its own annual revenue of just $3.6 million. The uncertainty over whether the acquisition will close has become the single biggest swing factor for the stock.
Should investors sell immediately? Or is it worth buying Diginex?
Operating progress amid the drama
Away from the takeover paralysis, the core business continues to notch gains. The Matter subsidiary has boosted its AI‑powered data extraction automation rate from 25% to 80%, serving large clients that collectively oversee $20 trillion in assets under management. Meanwhile, the company is pressing ahead with an internal restructuring that merges four operating units — Plan A.Earth, Matter DK, The Remedy Project and others — into a single integrated platform for environmental, social and governance (ESG) and supply chain risk management.
This consolidation is designed to create a unified product story, potentially complementing the new Risk‑to‑Remedy offering. But for now, the strategic narrative is split between the organic growth story and the binary overhang of the Resulticks deadline.
Chart support and the next trigger
Technically, the stock is trapped in oversold territory with no clear catalyst to reverse the slide. The $0.90 level has emerged as a key support — a break below that could accelerate selling. Conversely, any confirmation that the Resulticks deal is moving forward would likely shift focus straight back to the company’s operational momentum and the new product pipeline.
Market observers expect another week of outsized moves. Each passing day without an official statement raises the perceived risk of the transaction falling apart. If the deal does collapse, Diginex will have to rely on its organic growth initiatives — including Risk‑to‑Remedy — to fill the gap. With the regulatory clock now running on a slower schedule, the company may have time to prove its standalone value, but the patience of shareholders is clearly wearing thin.
Ad
Diginex Stock: Buy or Sell?! New Diginex Analysis from June 14 delivers the answer:
The latest Diginex figures speak for themselves: Urgent action needed for Diginex investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 14.
Diginex: Buy or sell? Read more here...
